Startups

TCR-based immunotherapies developer targeting novel dark antigens for cancer patients.

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 23,000 COMPANIES →

Summary

Seedtable Score

Score icon 72

Last Stage Round

Total Funding
$32.5M

Full Company Profile